Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
BioWorld25d
Vertex wins FDA nod for Journavx, new mechanism for acute pain
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
Taiwan News26d
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...
Stockhouse26d
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...
Nasdaq26d
Silexion Therapeutics Corp. Announces $3.3 Million Warrant Exercise and New Private Placement Financing
Silexion Therapeutics Corp. announced the immediate exercise of outstanding warrants to purchase 2,221,523 ordinary shares at an exercise price of $1.35 per share, expected to yield approximately ...
stockstelegraph27d
DJT Shares Climb As Trump Media Unveils Growth Plans
Shares of Trump Media & Technology Group Corp. (NASDAQ: DJT) experienced a notable increase following the company’s announcement of a strategic expansion into financial services and financial ...